Présentation de l'entreprise
Aveanna Healthcare Holdings Inc. operates as a diversified home care platform company that delivers pediatric and adult healthcare services throughout the United States, enabling patients to receive treatment within their own residences while minimizing reliance on high-cost institutional settings. The enterprise functions within the healthcare sector, specifically under the medical care facilities industry, positioning it to capitalize on trends toward outpatient and community-based care delivery models. The company's current market capitalization stands at $1.44 billion, supported by an annual revenue run rate of $2.43 billion and a workforce comprising 3,500 employees. These valuation and operational metrics indicate that Aveanna holds a substantial position in the domestic healthcare infrastructure, reflecting a significant asset base that generates billions in top-line activity despite operating in a capital-intensive service environment.
Santé financière
The company reported total revenue of $2.43 billion over the trailing twelve months, generating net income of $225.03 million and EBITDA of $289.08 million during the same period. The substantial gap between the $2.43 billion in revenue and the $225.03 million in net income reveals a cost structure where operating expenses and taxes consume approximately 90.8% of gross receipts before arriving at the bottom line. Free cash flow for the period amounted to $79.12 million, a figure that represents the actual cash available after capital expenditures, providing the firm with financial flexibility to service obligations or fund operational needs without immediate reliance on external financing. The gross margin stands at 33.1%, indicating that the company retains one-third of revenue after direct costs of services are deducted, while the operating margin of 11.4% and profit margin of 9.2% demonstrate the efficiency of overhead management and final profitability relative to sales. Liquidity and leverage profiles show a cash balance of $197.16 million against total debt of $1.51 billion, resulting in a debt-to-equity ratio of 775.91 which characterizes a highly leveraged balance sheet rather than a conservative one. The current ratio of 1.32 suggests that the company possesses sufficient current assets to cover short-term liabilities, though the margin is relatively tight given the heavy debt load. Return on equity is reported at 615.7% and return on assets at 9.5%, metrics that highlight the intense leverage amplifying equity returns while asset turnover efficiency remains moderate relative to the equity base.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is 6.14, whereas the forward P/E ratio stands at 9.49, implying that the market expects earnings to increase significantly in the coming year as the forward multiple is higher than the historical multiple. The price-to-book ratio is 7.17, which indicates that the market values the company at more than seven times its book value, suggesting a significant premium assigned to its intangible assets, brand, or future growth prospects relative to its tangible net worth. Alternative valuation metrics such as the price-to-sales ratio of 0.59 and the EV/EBITDA of 9.55 provide different perspectives on value, with the low P/S ratio suggesting the stock trades at a fraction of its revenue base compared to typical tech or biotech peers, while the EV/EBITDA reflects the enterprise value relative to cash earnings before interest and taxes. Over the past year, the stock price fluctuated between a low of $3.73 and a high of $10.32, and without the current exact share price provided in the facts, the precise percentage deviation from the 52-week high cannot be calculated, though the range defines the volatility corridor for recent trading activity. The beta of 2.09 indicates that the stock price exhibits more than double the volatility of the broader market, meaning it tends to rise and fall with greater intensity than the general equity index during periods of market movement.
Growth & Income
Revenue growth year-over-year reached 27.4%, while earnings growth year-over-year accelerated to 465.2%, demonstrating that profitability is expanding at a rate significantly faster than top-line revenue, which often implies leverage effects from cost controls or margin expansion. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all of its net income rather than distributing it to shareholders. This reinvestment strategy directs earnings toward business expansion, debt reduction, or share buybacks rather than providing immediate income to investors. Consequently, the overall growth and income profile is characterized by aggressive earnings expansion and zero current yield, relying entirely on capital appreciation potential and future earnings growth to generate returns for equity holders.